Why We Should Treat COVID-19 Long Hauler Syndromes with Convalescent Plasma; Contained Suppressive Exosomes Are Likely COVID Antigen-Specific
April 2021
Studysummary This study proposes that neutralizing antibodies and exosomes in convalescent plasma may interfere with early immune responses, potentially explaining limited success of this therapy in active COVID-19 infections.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on osf.io →